So you think it will just be one question they’re voting on and then the FDA will apply a label based on the vote and the discussion that happens at Adcom?
I agree, that while many topics will be discussed during the meeting, the committee will be asked to vote on one question. I am predicting that the final question will be something similar to this,
"Taking into account the described efficacy and safety data for Vascepa, do you believe that its effects on the described cardiovascular outcomes are sufficient to grant approval for co-administration with statin therapy for primary prevention? Please provide the rationale underlying your recommendation."
I think this is where the research is weakest, and I would not be surprised if the question is even more narrow to specifically address "patients had diabetes mellitus and at least one additional risk factor" as described in REDUCE-IT.
JL, if that is the panel question, why don't they just post the answer 48 hours before adcom! Lol! A resounding YES! I'm leaning towards adcom is all about the label.